Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Jennifer Doudna & Feng Zhang
Business

As CRISPR patent fight nears the endgame, where are settlement talks?

By Sharon Begley

Biogen over the hill
Biotech

As Biogen turns 40, biotech worries the glory days may be over

By Damian Garde

Express Scripts flag
Biotech

Saddled with sluggish sales, Regeneron and Sanofi slash the cost of cholesterol-lowering drug

By Damian Garde

Glass vials
Biotech

Corners of the immunotherapy space are getting crowded. Is that a problem?

By Meghana Keshavan

Biotech

Karyopharm to pursue FDA approval for multiple myeloma drug based on new study results

By Adam Feuerstein

Peter Thiel
Biotech

Another drug acquired from Peter Thiel-backed biotech appears to have flopped

By Rebecca Robbins

Celgene
Adam's Take

Celgene’s beaten-down stock is cheap, but only if investors regain trust in its financial outlook

By Adam Feuerstein

Cash
Adam's Take

This biotech CEO’s lousy job performance cost shareholders money, so his board docked his pay

By Adam Feuerstein

Isaly CNBC Screen Cap
Biotech

Sam Isaly leaves OrbiMed months after harassment allegations

By Damian Garde

CRISPR
Business

All you need to know for round 2 of the CRISPR patent fight

By Sharon Begley

The Readout LOUD

LISTEN: Megamergers, migraines, and biotech’s Four Horsemen

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Vertex
Business

Vertex’s latest cystic fibrosis drug reports strong sales in first quarter since approval

By Adam Feuerstein

CRISPR-CAS9 illustration
Biotech

Doudna’s latest CRISPR company debuts, joining the crowds in diagnostics and genome-editing

By Sharon Begley

Scott Gottlieb -opioid addiction
Business

FDA could convene second advisory panel to re-examine safety of Acadia Pharma drug

By Damian Garde and Adam Feuerstein

Amgen
Business

Amgen still has no magic pill to solve its zero-growth problem

By Adam Feuerstein and Damian Garde

Alex Azar - Sworn In At The White House
Politics

Drug makers question idea to shake up how Medicare pays for certain drugs

By Erin Mershon and Ike Swetlitz

Biotech

Biogen’s rain-making rare-disease drug hits a sales slump

By Damian Garde

Food addiction
In the Lab

They were commercial flops. But can weight loss drugs be used to treat addiction?

By Meghana Keshavan

Biotech

Prothena scraps lead drug following mid-stage study failure

By Adam Feuerstein

Adam's Take

SEC extends probe into Northwest Biotherapeutics as financial struggles mount

By Adam Feuerstein

Interacting chromatin chains
Biotech

Startup unwinds the role of chromatin to target epigenetic changes in cancer

By Elizabeth Cooney

Novartis International pharmaceutical
Biotech

For the first CAR-T therapy, early sales are weak but hopes are still sky high

By Damian Garde

Dr. John Maraganore
Biotech

Trade secrets battle between Alnylam, Dicerna is just one of many

By Jonathan Saltzman — Boston Globe

Merck logo
Biotech

Merck extends its lead in immuno-oncology with ‘practice-changing’ lung cancer data

By Damian Garde

FDA campus
Biotech

Alkermes’s depression drug is back on track after an FDA ‘misunderstanding’

By Damian Garde

Akili screenshot
Business

A digital medicine company tries to adopt pharma’s patent game. Will it work?

By Rebecca Robbins

Biotech

Pfizer latest to test gene therapy for Duchenne muscular dystrophy

By Elizabeth Cooney

Elizabeth Holmes
Business

‘Therabros’ and ‘disappeared’ staffers: the 8 juiciest things we learned from John Carreyrou’s new Theranos book

By Rebecca Robbins

Alexion Pharmaceuticals Inc
Business

Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline

By Adam Feuerstein

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.